M&A Science reports that Eli Lilly and Company added Merida Biosciences to its 2026 shopping list, committing up to $2.88B for an antibody-engineering platform focused on Graves' disease and thyroid eye disease.
Public source
Publisher name
Public post
Eli Lilly and Company just added Merida Biosciences to its 2026 shopping list; up to $2.88B for an antibody-engineering platform going after Graves' disease and thyroid…
Company
M&A Science
Exploring better ways to do M&A
- Industry
- Think Tanks
- Location
- Chicago, Illinois, US
- Company size
- 11–50 employees
About M&A Science
M&A Science is the leading podcast for modern M&A practitioners. We bring together the industry’s top experts to share real-world lessons on how to lead deals more effectively—from sourcing and diligence to integration. Each episode uncovers practical strategies to modernize the M&A process and build a scalable, Buyer-Led M&A™ function.
See moreLatest activity
Latest activity from M&A Science
7 signals
Partnerships
M&A Science reports that Tesia Hostetler and Johanna Jaakola are involved in the integration process at Cisco before the LOI is signed.
Capital & Finance
M&A Science noted that Anthropic walked away from a $6 billion acquisition reported by Decart, the AI infrastructure startup Bloomberg, circling back in August.
Customers & Market
M&A Science experienced three rounds of renegotiation to get back to a number agreed upon by the founder and co-founder.
Discover more
Similar signals
Similar public activity from other companies.
Strategy & Corporate Development
Labiotech.eu
Labiotech.eu reports that Eli Lilly and Company acquired Merida Biosciences for up to $2.875 billion, with Merida Biosciences leading asset MER511 acquired.
Strategy & Corporate Development
Merida Biosciences
Merida Biosciences entered into a definitive agreement to be acquired by Eli Lilly and Company to advance treatments for serious autoimmune and allergic diseases.
Strategy & Corporate Development
SciSure
SciSure reported that Eli Lilly is acquiring Merida Biosciences for up to $2.875B.
Strategy & Corporate Development
LifeSci Search
LifeSci Search noted that Eli Lilly and Company's planned acquisition of AtaiBeckley is an interesting moment to look back at how the company and its board of directors evolved.
Strategy & Corporate Development
Third Rock Ventures